Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

STATE MEDICAID FORMULARY COVERAGE OF OTC DRUGS RECOMMENDED

This article was originally published in The Tan Sheet

Executive Summary

STATE MEDICAID FORMULARY COVERAGE OF OTC DRUGS RECOMMENDED in testimony from Iowa Medical Services Administrator Donald Herman before Rep. Henry Waxman's (D-Calif.) Energy & Commerce/health subcommittee on April 1. Herman suggested that state formularies "should not only be utilized for prescription drugs, but for over- the-counter medications as well." Highlighting the effectiveness of OTCs and their potential for cost savings, Herman testified that "over-the-counter medications should be an integral part of the formulary as many OTCs can be used as drugs of choice for medical problems, and negative economic results may occur if [they are] excluded." Waxman convened the April 1 hearing to discuss the Clinton Administration's proposal to reduce federal outlays for Medicaid by $ 7.8 bil. over the next five years, which is called for in this year's budget resolution. The administration is pushing to remove the prohibition against restrictive state formularies that was established as part of the prescription drug rebate program under Medicaid in the OBRA 1990 legislation. Presenting the views of the states at the hearing, Herman said that the state Medicaid agencies "need as many options as possible to manage their drug programs in a cost effective manner." He maintained that "a drug formulary is an option which states should be allowed to utilize."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel